FDA approves pill version of Novo Nordisk’s Wegovy, possibly widening access
The Food and Drug Administration on Monday approved the oral version of Novo Nordisk’s injectable weight loss drug Wegovy, making it the first GLP-1 pill to be cleared by regulators for obesity and possibly allowing many more Americans to get access to a highly effective treatment.
The Wegovy pill whose approval for weight loss was widely anticipated, has also been approved to reduce cardiovascular risks, similar to the injectable version.
Elaine Chen
Go to statnews